CHINA MED&HCARE(00383)

Search documents
中国医疗网络(00383) - 2023 - 中期业绩
2023-08-18 14:30
Financial Performance - The company's revenue for the six months ended June 30, 2023, was HKD 760,951,000, representing an increase of 3.1% compared to HKD 736,020,000 for the same period in 2022[8]. - The total comprehensive income for the period was a loss of HKD 8,824,000, compared to a loss of HKD 64,389,000 in the previous year, indicating a significant improvement[5]. - The net profit for the period was HKD 564,000, a recovery from a loss of HKD 39,810,000 in the same period last year[10]. - The total revenue for the six months ended June 30, 2023, was HKD 760,951,000, compared to HKD 736,020,000 for the same period in 2022, reflecting a growth of approximately 3.4%[101]. - The loss attributable to shareholders for the six months ended June 30, 2023, was HKD 1,755,000, a significant decrease of approximately 96.0% compared to a loss of HKD 43,902,000 in the same period of 2022[135]. - The group recorded a loss of HKD 19,296,000 for the period, compared to a loss of HKD 17,055,000 in 2022, including a fair value gain of HKD 1,887,000 from investment properties[68]. - The company reported a pre-tax loss of HKD 39,038,000 for the six months ended June 30, 2023[107]. - The net profit before tax for the period was HKD 2,802,000[147]. Revenue Streams - The medical division recorded revenue growth to 733,887,000 HKD for the six months ended June 30, 2023, up from 705,153,000 HKD in 2022, with profit rising to 32,329,000 HKD from 1,588,000 HKD[36]. - The company reported revenue from hospital fees and charges of HKD 733,887,000 for the six months ended June 30, 2023, an increase from HKD 705,153,000 in the same period last year, representing a growth of approximately 3.5%[101]. - Revenue from elderly care services and nutritional product sales reached HKD 18,765,000, up from HKD 17,585,000, indicating an increase of about 6.7% year-over-year[101]. - The aged care division's revenue decreased to 22,952,000 HKD for the six months ended June 30, 2023, down from 27,852,000 HKD in 2022 due to ongoing pandemic impacts[40]. Assets and Liabilities - The total assets as of June 30, 2023, were HKD 2,162,953,000, a decrease from HKD 2,199,101,000 at the end of 2022[16]. - The total assets as of June 30, 2023, amounted to HKD 3,439,059,000, compared to HKD 3,232,534,000 as of December 31, 2022[121]. - Total liabilities as of June 30, 2023, were HKD 1,559,732,000, compared to HKD 1,653,675,000 as of December 31, 2022, indicating a reduction in liabilities[121]. - The total liabilities increased to HKD 514,248,000 from HKD 419,705,000[162]. - The group's investment properties were valued at HKD 312,735,000 as of June 30, 2023, down from HKD 352,116,000 in 2022[79]. Cash Flow and Financing - The company reported other income of HKD 4,077,000, compared to HKD 2,064,000 in the previous year, showing growth in additional revenue streams[14]. - The company's cash and cash equivalents increased to HKD 822,019,000 from HKD 589,050,000, indicating improved liquidity[16]. - The company incurred financing costs of HKD 26,520,000, down from HKD 31,571,000, reflecting a reduction in interest expenses[24]. - The total borrowings of the group reached HKD 756,698,000 as of June 30, 2023, down from HKD 907,011,000 in 2022, with HKD 487,886,000 due within one year[76]. Operational Highlights - The number of outpatient visits at Deyi Hospital increased to 8,915 in the first half of 2023, up from 6,305 in 2022, while inpatient visits rose to 4,597 from 4,358[69]. - The medical division's Kunming Hospital recorded an increase in business volume, with 16,203 inpatient visits compared to 13,536 in the previous year[140]. - The company has 55 serviced apartments rented out, an increase from 54 in the previous year[141]. - The company sold 857 out of 868 independent living units in its retirement community, with 347 residents moved in[141]. Strategic Initiatives - The company plans to enhance communication with local long-term care insurance institutions to improve occupancy rates in the aged care division[41]. - The group plans to enhance its medical services by focusing on high-demand specialties such as ophthalmology, aesthetic medicine, and dentistry, aiming to attract mid-to-high-end clients[186]. - The company plans to continue its sustainable growth strategy in the second half of the year, focusing on cost control and efficiency improvements[83]. - The company aims to enhance service quality and operational efficiency by emphasizing detail management and identifying key drivers for cost reduction[85]. - The group has established a medical alliance with Nanjing University of Aeronautics and Astronautics to strengthen marketing and public relations efforts[65]. Market and Economic Conditions - The group anticipates ongoing uncertainties in the global economy and business environment, which may impact consumer confidence and business operations[188]. - The company has maintained compliance with the corporate governance code as per the Hong Kong Stock Exchange regulations[87]. Investment and Development - The second phase of the Kunming Hospital construction is progressing, with the foundation work completed for the tumor and nuclear medicine building[39]. - The group has no significant investments or acquisitions of subsidiaries, associates, or joint ventures during the reporting period[53]. - The group’s available-for-sale development properties were valued at HKD 140,000,000 as of June 30, 2023, compared to HKD 149,914,000 in 2022[79]. - The group reported a net current asset value of HKD 120,845,000 as of June 30, 2023, compared to a net current liability value of HKD 172,195,000 in 2022[177].
中国医疗网络(00383) - 2022 - 年度财报
2023-04-27 12:00
Shareholding and Capital Structure - Cool Clouds, a wholly-owned subsidiary of Resuccess, holds 4,000,000,000 ordinary shares, representing 27.62% of the company's total issued shares as of December 31, 2022[2][16]. - The total issued share capital of the company is 14,480,072,773 shares as of December 31, 2022[15][18]. - The company has a diverse shareholder base, with significant holdings including 21.70% by Li Chenghui and related parties[16]. - The company has completed a share consolidation, reducing the total issued shares from 14,480,072,773 to 724,003,638 shares as of February 24, 2023[199]. - The company announced a proposed share consolidation, merging every 20 existing shares with a par value of HKD 0.0005 into 1 consolidated share with a par value of HKD 0.01[174]. - The trading unit on the Stock Exchange will change from 10,000 existing shares to 5,000 consolidated shares after the consolidation takes effect[174]. Financial Performance - The total revenue for the year ended December 31, 2022, was HKD 1,437,863,000, a decrease of approximately 1.9% compared to HKD 1,465,679,000 for the year ended December 31, 2021[42]. - The loss attributable to the owners of the company for the year was HKD 123,574,000, which is a reduction of about 10.0% compared to HKD 137,296,000 in the previous year; however, excluding the impairment loss on receivables, the loss increased by approximately 80.5%[42]. - As of December 31, 2022, the net asset value per share was HKD 2.15, down from HKD 2.35 in the previous year[43]. - The company did not recommend the payment of a final dividend for the year, consistent with the previous year[31]. - For the year ended December 31, 2022, the basic loss per share was HKD 0.1707, compared to HKD 0.1896 for the previous year[62]. Business Operations - The company’s main business includes investment, management, and operation of healthcare and hospital services, elderly care services, and trading of medical equipment[45]. - Nanjing Hospital has established a laboratory for otolaryngology and head and neck surgery, enhancing its medical expertise and influence[48]. - The company has signed cooperation letters with four insurance companies to integrate commercial insurance with healthcare services[49]. - The medical division's Nanjing Hospital recorded a total of 2,961,246 outpatient visits, an increase from 1,180,171 visits in the previous year[69]. - The revenue from the elderly care business decreased to HKD 49,787,000, down from HKD 79,889,000 in the previous year, with a loss of HKD 51,169,000 compared to HKD 72,135,000[70]. - The property development segment reported revenue of HKD 732,000, a significant drop from HKD 6,803,000, resulting in a loss of HKD 24,329,000 compared to a profit of HKD 439,000 in the previous year[73]. - Rental income from investment properties increased to HKD 5,188,000, up from HKD 4,756,000, but the segment incurred a loss of HKD 9,397,000 compared to a profit of HKD 6,296,000 in the previous year[74]. - The total number of doctors at Nanjing Hospital was 403, with 525 nurses and 1,144 beds, compared to 402 doctors, 532 nurses, and 1,015 beds in the previous year[69]. - The company established a high blood pressure management center, officially passing national certification, and launched night consultation services in Kunming Hospital[89]. - The company conducted 19 public welfare activities throughout the year, strengthening community engagement and establishing a public welfare image[88]. Compliance and Governance - The company has complied with all regulatory requirements regarding board member disclosures and re-elections[6][19]. - The company has maintained compliance with the Securities and Futures Ordinance regarding the disclosure of interests in shares[14]. - The company is committed to compliance with applicable laws and regulations, with no known significant non-compliance issues during the year[25]. - The company is committed to high standards of corporate governance, believing it is key to success and enhancing shareholder value[177]. - The company’s financial statements were audited by a recognized firm, ensuring accuracy and compliance[173]. - The board consists of 10 members, including 4 executive directors, 2 non-executive directors, and 4 independent non-executive directors[178]. - The independent non-executive directors attended board meetings with attendance rates ranging from 86% to 100%[181]. - The board of directors has adopted a compensation model for determining the remuneration of directors and senior management, considering their roles and current market conditions[193]. Financial Position and Liabilities - As of December 31, 2022, the total borrowings of the group reached HKD 933,603,000, an increase from HKD 919,940,000 in 2021[104]. - The group recorded a net current liability of HKD 97,285,000 as of December 31, 2022, down from HKD 356,380,000 in 2021[105]. - The group has unutilized, unsecured credit facilities of HKD 415,000,000 for more than one year as of December 31, 2022[105]. - The group has capital commitments for property, plant, and equipment amounting to HKD 276,746,000 as of December 31, 2022, compared to HKD 30,692,000 in 2021[109]. - The group's debt ratio was approximately 20.2% as of December 31, 2022, compared to 16.5% in 2021[129]. - The group recorded a loss of HKD 5,202,000 in its lending business for the year, an improvement from a loss of HKD 75,000,000 in 2021[126]. - The group has no significant contingent liabilities as of December 31, 2022[110]. Future Outlook and Strategy - The group plans to cautiously implement the second phase of Kunming Hospital and continue developing high-end outpatient clinics in Nanjing in 2023[113]. - The group anticipates ongoing volatility in the economic and business environment due to geopolitical conflicts, rising global inflation, and long-term impacts of the pandemic[116]. - The group will continue to review and adjust its business and investment strategies to adapt to the challenging economic environment[116]. - The medical division will focus on improving operational management to enhance revenue streams, service quality, and cost control, while emphasizing research and development and attracting academic leaders[136]. - In 2023, the division plans to increase nursing home occupancy rates and adjust the operational model of serviced apartments to improve overall operational performance[136]. - The division aims to enhance customer experience for the elderly through free medical consultations and more community activities, thereby retaining community clients and improving service reputation[136]. - Significant marketing program innovations will be implemented, including community promotions and establishing self-media to attract potential customers[136]. - The division will enhance internal management, optimize products and services, and refine operational cost management to improve quality and efficiency[136]. - Frontline staff salaries will be increased to encourage employees to maintain service quality[136]. Employment and Human Resources - The group employed 2,577 employees as of December 31, 2022, an increase from 2,492 employees in 2021[135]. - The remuneration of directors and senior management is determined based on operational performance and market statistics[169]. - The company has implemented a salary policy determined by management based on employee merits, qualifications, and capabilities[192]. - The board of directors received comprehensive training to ensure understanding of the company's operations and regulatory responsibilities[185]. Related Party Transactions - There were related party transactions during the year, which were fully exempt from the related party transaction regulations[168]. - The company has no major customers or suppliers due to the nature of its primary business[167]. - The company has not disclosed any major customers or suppliers in the provided documents[189].
中国医疗网络(00383) - 2022 - 年度业绩
2023-03-28 14:44
香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責,對其準確性或 完整性亦不發表任何聲明,並明確表示,概不就因本公告全部或任何部份內容而產生或因倚賴該 等內容而引致之任何損失承擔任何責任。 China Medical & HealthCare Group Limited 中 國 醫 療 網 絡 有 限 公 司 (於百慕達註冊成立之有限公司) (股份代號:383) 截至二零二二年十二月三十一日止之年度業績公告 中國醫療網絡有限公司(「本公司」)之董事會(分別為「董事」及「董事會」)謹此宣佈, 本公司及其附屬公司(統稱為「本集團」)截至二零二二年十二月三十一日止年度之 經審核綜合業績連同截至二零二一年十二月三十一日止年度之比較數字如下: 綜合損益表 截至二零二二年十二月三十一日止年度 二零二二年 二零二一年 附註 千港元 千港元 收入 3 1,437,863 1,463,495 出售持作買賣之投資所得款項總額 — 2,184 總額 1,437,863 1,465,679 ...
中国医疗网络(00383) - 2022 - 中期财报
2022-09-28 09:00
Financial Performance - The total revenue for the six months ended June 30, 2022, was HKD 736,020, an increase of 3.6% compared to HKD 710,856 for the same period in 2021[2]. - The gross profit for the period was HKD 117,467, down from HKD 136,563 in the previous year, reflecting a decrease of approximately 14%[2]. - The net loss for the six months ended June 30, 2022, was HKD 39,810, a significant improvement compared to a net loss of HKD 65,779 in the same period of 2021, representing a reduction of about 39.4%[2]. - The basic loss per share for the period was HKD 0.30, compared to HKD 0.51 for the same period last year[4]. - The total comprehensive loss for the period was HKD 64,389, compared to HKD 57,498 in the previous year, indicating an increase in losses[6]. - Cash generated from operating activities was HKD 23,801,000, a significant decrease from HKD 81,675,000 in the prior year[14]. - The company experienced a net cash outflow from operating activities of HKD 8,391,000, compared to a net inflow of HKD 41,763,000 in the previous year[14]. - The company reported a significant foreign exchange loss of HKD 24,505 during the period, compared to a gain of HKD 8,196 in the previous year[6]. - The company reported a net loss of HKD 39,810,000 for the six months ended June 30, 2022[19]. - The loss attributable to the company's owners for the same period was HKD 43,902,000, a decrease of approximately 40.6% from HKD 73,899,000 in the first half of 2021[99]. Revenue Breakdown - Revenue from hospital fees and charges increased to HKD 705,153,000, up from HKD 662,217,000 in the same period last year, representing a growth of approximately 6.5%[24]. - Total revenue for the six months ended June 30, 2022, was HKD 732,685,000, with medical services contributing HKD 705,153,000, elderly care services HKD 27,151,000, and property development HKD 381,000[26]. - Revenue from inpatient medical services was HKD 251,820,000, outpatient medical services HKD 238,573,000, and other medical services HKD 5,689,000[26]. - The elderly care services generated revenue of HKD 13,919,000, while nutrition product sales contributed HKD 3,666,000[26]. - Property sales accounted for HKD 9,566,000, leading to a total of HKD 9,947,000 from property development[26]. - Revenue recognized at a point in time was HKD 708,036,000, while revenue recognized over time was HKD 24,649,000[26]. Assets and Liabilities - Non-current assets decreased to HKD 2,214,251 as of June 30, 2022, from HKD 2,507,443 as of December 31, 2021, indicating a decline of approximately 11.7%[8]. - Current liabilities amounted to HKD 1,300,720, a slight decrease from HKD 1,338,475 at the end of 2021[10]. - The total assets less current liabilities stood at HKD 2,042,056, a decrease from HKD 2,151,063 at the end of 2021[10]. - Total liabilities as of June 30, 2022, were HKD 1,689,909,000, with medical segment liabilities at HKD 1,132,518,000[49]. - The company’s current liabilities exceeded its current assets as of June 30, 2022, indicating potential liquidity issues[19]. - The total value of mortgaged assets as of June 30, 2022, was HKD 887,303,000, compared to HKD 882,295,000 as of December 31, 2021[87]. Operational Highlights - The company operates in three main segments: medical services, elderly care, and property development, all primarily in mainland China[40]. - The company established medical alliance agreements with Nanjing Mingzhou Rehabilitation Hospital and Southeast University Hospital to enhance cooperation in medical projects[107]. - The company is expanding its high-end comprehensive clinic services in Nanjing, with ongoing renovations to provide a wide range of medical services[107]. - The Kunming Hospital recorded a total of 171,452 outpatient visits, an increase from 134,820 visits in the previous year, and 8,520 inpatient admissions, up from 7,294 admissions[112]. - The Nanjing Hospital achieved 1,340,016 outpatient visits, significantly higher than 491,565 visits in the previous year, and 13,536 inpatient admissions, slightly down from 14,412 admissions[112]. Challenges and Future Outlook - The company continues to face significant uncertainty due to the ongoing economic conditions and the impact of the COVID-19 pandemic on demand for its services and products[21]. - The elderly care division anticipates continued operational impacts from the severe pandemic situation in the second half of 2022, with a focus on maintaining stable operations[146]. - The company expects ongoing volatility in the economic and business environment due to factors such as COVID-19 variants, geopolitical tensions, and rising interest rates[148]. - The company will maintain a prudent approach and continue to review and adjust its business and investment strategies to adapt to the challenging economic environment[148]. Shareholder Information - Major shareholders include Tongfang Co., Ltd. and Resuccess Investments Limited, each holding approximately 27.62% of the issued shares[156]. - The company’s executive Ms. Zhuang holds a total of 2,604,889,140 shares, representing approximately 17.99% of the issued ordinary shares[149]. - Major shareholders include Tianan China Investment Limited holding 1,857,529,625 shares, representing 12.82% of the issued ordinary shares[160]. - The total issued share capital of the company as of June 30, 2022, is 14,480,072,773 shares[160]. Governance and Compliance - The company has complied with the corporate governance code as per the listing rules during the six months ending June 30, 2022[166]. - The audit committee reviewed the accounting principles and practices adopted by the group, including the interim financial statements for the six months ending June 30, 2022[165]. - The board of directors confirmed compliance with the standard code of conduct for securities transactions during the six months ending June 30, 2022[167].
中国医疗网络(00383) - 2021 - 年度财报
2022-04-28 09:38
Financial Performance - The total revenue for the year ended December 31, 2021, was HKD 1,465,679,000, an increase from HKD 1,197,396,000 in 2020[9] - The company reported a loss attributable to owners of HKD 137,296,000 for the year, compared to a loss of HKD 111,928,000 in 2020, primarily due to increased impairment losses on financial assets of HKD 68,905,000[9] - The basic loss per share for the year was HKD 0.948, compared to HKD 0.773 in 2020[9] - The net asset value per share as of December 31, 2021, was HKD 0.117, down from HKD 0.123 in 2020[10] Medical Segment Performance - The medical segment generated revenue of HKD 1,372,032,000, up from HKD 1,093,752,000 in 2020, with a profit increase to HKD 59,573,000 from HKD 31,728,000[14] - The EBITDA for the medical segment was HKD 195,567,000, an increase from HKD 174,073,000 in 2020[14] - Nanjing Hospital recorded a total of 1,180,171 outpatient visits in 2021, up from 712,829 in 2020, and 27,154 inpatient admissions, slightly increasing from 27,062 in 2020[23] - Kunming Hospital achieved 299,951 outpatient visits in 2021, compared to 229,930 in 2020, and 15,917 inpatient admissions, up from 13,441 in 2020[23] Elderly Care Division - The elderly care division reported a revenue decline to HKD 79,889,000 in 2021 from HKD 82,392,000 in 2020, with losses increasing to HKD 72,135,000 from HKD 34,845,000[24] - The group provided home care services to 34 elderly individuals, with a total of 5,419 visits in 2021, down from 46 individuals and 7,143 visits in 2020[26] - The elderly care division aims to enhance marketing efforts to promote elderly care products and services, and will introduce home care services[62] Property and Investment Performance - As of December 31, 2021, the investment property portfolio of the group, which is 100% owned, includes serviced apartments with a total construction area of 25,804 square meters and retail shopping areas with a total construction area of 9,334 square meters, with a total book value of HKD 549,570,000, up from HKD 530,396,000 in 2020[28] - For the property development business, the group recorded revenue of HKD 6,803,000 in 2021, down from HKD 11,851,000 in 2020, but achieved a profit of HKD 439,000 compared to a loss of HKD 1,638,000 in the previous year[29] - The investment property segment generated rental income of HKD 4,756,000 in 2021, down from HKD 6,125,000 in 2020, while achieving a profit of HKD 6,296,000 compared to a loss of HKD 2,986,000 in 2020[30] Debt and Financial Position - The total borrowings of the group reached HKD 919,940,000 as of December 31, 2021, down from HKD 971,379,000 in 2020[43] - The group's debt ratio, calculated as net borrowings divided by total equity, was 16.5% as of December 31, 2021, compared to 17.9% in 2020[44] - The group recorded a full impairment loss provision of HKD 68,846,000 for the loan, significantly higher than HKD 22,468,000 in 2020[40] Corporate Governance - The company has a diverse board with members experienced in finance, law, and engineering, enhancing its governance and strategic direction[70] - The company is focused on expanding its market presence and enhancing operational efficiency through experienced leadership[71] - The board's composition reflects a commitment to corporate governance and strategic oversight in the healthcare sector[72] - The company has implemented measures to maintain high standards of corporate governance[123] Shareholder Information - As of December 31, 2021, the company had a total of 14,480,072,773 shares issued, with a significant shareholder, Vigor Online Offshore Limited, holding 2,592,514,140 shares, representing 17.90% of the total issued shares[96] - Major shareholders include Tongfang Co., Ltd. and Resuccess Investments Limited, each holding 4,000,000,000 shares, accounting for 27.62% of the total issued shares[101] - The company reported no final dividend for the year ended December 31, 2021, consistent with the previous year[86] Future Plans and Strategies - The company plans to continue expanding its operations despite the challenges posed by the COVID-19 pandemic[14] - In 2022, the medical division plans to cautiously implement the development of key strategic projects, including the second phase of Kunming Hospital and the Nuclear Medicine Center in Nanjing[60] - The company aims to achieve sustainable quality development and become a long-lasting sustainable enterprise[200] Community and Social Responsibility - The company has launched multiple public welfare projects, providing health checks and community services to share economic benefits with those in need[200] - The company is committed to a zero-tolerance policy towards unethical behavior and corruption, promoting a culture of integrity[199] - The company continues to engage with employees, patients, customers, and the community to combat the pandemic and encourage mutual support[200]
中国医疗网络(00383) - 2021 - 中期财报
2021-09-29 09:34
Financial Performance - The company reported unaudited revenue of HKD 708,672,000 for the six months ended June 30, 2021, representing a 50% increase from HKD 472,937,000 in the same period of 2020[2]. - Gross profit for the same period was HKD 136,563,000, up from HKD 87,301,000, indicating a gross margin improvement[2]. - The company incurred a loss before tax of HKD 59,721,000, an improvement from a loss of HKD 67,253,000 in the prior year[5]. - The net loss for the period was HKD 65,779,000, compared to a net loss of HKD 67,912,000 in the previous year, showing a slight reduction in losses[5]. - Total revenue for the six months ended June 30, 2021, was HKD 708,672,000, representing a 49.8% increase from HKD 472,937,000 in the same period of 2020[36]. - The group reported a net loss before tax of HKD 59.721 million for the six months ended June 30, 2021, compared to a loss of HKD 67.253 million for the same period in 2020[82]. - The company reported a total loss of HKD (73,899,000) for the six months ended June 30, 2021, compared to a loss of HKD (70,015,000) in the same period in 2020, indicating a 4.1% increase in losses[10][11]. Revenue Breakdown - Revenue from hospital fees and charges was HKD 662,217,000, up 53.0% from HKD 432,839,000 year-on-year[36]. - Revenue from elderly care-related services and nutritional product sales was HKD 19,497,000, a slight increase of 7.3% from HKD 18,165,000 in the previous year[36]. - Revenue from property development sales was HKD 6,074,000, significantly up from HKD 927,000 in the same period last year, marking a 553.0% increase[36]. - Revenue from medical services, including inpatient and outpatient services, accounted for HKD 258,520,000 and HKD 194,314,000 respectively, contributing to the overall medical revenue of HKD 662,217,000[40]. - The healthcare segment generated revenue of HKD 662,217,000 for the six months ended June 30, 2021, up from HKD 432,839,000 in the same period of 2020, with an EBITDA of HKD 93,539,000[156]. Assets and Liabilities - The company's total assets as of June 30, 2021, were HKD 2,240,739,000, down from HKD 2,297,450,000 at the end of 2020[14]. - Current liabilities increased to HKD 1,195,685,000 from HKD 1,127,724,000, reflecting a rise in operational obligations[14]. - The company’s equity attributable to owners decreased to HKD 1,721,164,000 from HKD 1,785,074,000, indicating a decline in shareholder equity[16]. - The group’s liabilities totaled HKD 1,675.135 million as of June 30, 2021, compared to HKD 1,624.540 million as of December 31, 2020[94]. - The total amount of trade receivables as of June 30, 2021, was HKD 201,732,000, a significant increase from HKD 136,301,000 as of December 31, 2020, reflecting a growth of 47.9%[14][15]. - The total outstanding loans as of June 30, 2021, were HKD 971,290,000, slightly down from HKD 971,379,000 as of December 31, 2020[133]. Cash Flow and Financing - For the six months ended June 30, 2021, the company reported a net cash inflow from operating activities of HKD 41,763,000, compared to a net outflow of HKD 107,137,000 in the same period of 2020[23]. - The company reported cash and cash equivalents of HKD 539,040,000, a decrease from HKD 616,474,000 at the end of 2020[14]. - New borrowings amounted to HKD 73,337,000, while repayments totaled HKD 81,089,000, resulting in a net cash outflow from financing activities of HKD 9,125,000[25]. - The company has access to a standby loan facility of HKD 300,000,000, which may provide additional liquidity if needed[28]. - The company’s total borrowings included HKD 216,234,000 in unsecured loans and HKD 228,131,000 in secured bank borrowings as of June 30, 2021[132]. Operational Highlights - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[2]. - The company is preparing for the certification assessment of a tertiary comprehensive hospital, with the application submitted in April 2021[158]. - Nanjing Hospital recorded a total of 491,565 outpatient visits, 14,412 inpatient admissions, and 28,546 examinations during the review period, representing increases from 293,876 outpatient visits, 11,989 inpatient admissions, and 15,472 examinations in 2020[161]. - The elderly care segment reported revenue of HKD 38,060,000, up from HKD 35,731,000 in 2020, but incurred a loss of HKD 11,492,000 compared to a loss of HKD 9,558,000 in the previous year[163]. - The company aims to enhance member satisfaction and service quality in its community village operations by integrating healthcare and elderly care services[164]. Investment and Capital Expenditures - The company’s investment in property, plant, and equipment amounted to HKD 70,780,000, up from HKD 41,658,000 in the previous year, reflecting ongoing capital expenditures[24]. - Capital expenditures for property, plant, and equipment amounted to HKD 37,590,000, while investment properties accounted for HKD 14,683,000 for the six months ended June 30, 2021[146]. - The group utilized HKD 153,994,000 for the purchase and improvement of medical and healthcare equipment[189]. Tax and Other Expenses - Tax expenses for the six months ended June 30, 2021, showed a significant increase in corporate income tax to HKD (6,109,000) from HKD (453,000) in 2020, reflecting a rise of 1247.9%[8][9]. - The company’s interest paid increased to HKD 29,930,000 from HKD 21,891,000 year-over-year, indicating rising financing costs[24]. - The group reported a foreign exchange loss of HKD 3.423 million for the six months ended June 30, 2021[97].
中国医疗网络(00383) - 2020 - 年度财报
2021-04-29 13:02
China Medical & HealthCare Group Limited 中 國 醫 療 網 絡 有 限 公 司 * (於百慕達註冊成立之有限公司) (股份代號: 383) 2020 年 報 * · 中文名稱值供最別 中國醫療網絡有限公司 目錄 公司資料 2 主席報告 3 董事簡介 20 董事會報告 24 企業管治報告 32 環境、社會及管治報告 49 獨立核數師報告 62 綜合損益表 68 綜合損益表及其他全面收益表 69 綜合財務狀況報表 70 綜合權益變動表 72 綜合現金流量表 73 綜合財務報表附註 75 財務概要 185 1 二零二零年年報 中國醫療網絡有限公司 | --- | --- | |---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...
中国医疗网络(00383) - 2020 - 中期财报
2020-09-29 22:20
China Medical & HealthCare Group Limited 中 國 醫 療 網 絡 有 限 公 司 * (於百慕達註冊成立之有限公司) (股份代號: 383) | --- | --- | |----------|--------------------| | | | | | | | 2020 | | | 中期報告 | | | | | | | * 中文名稱劇的服务 | 中國醫療網絡有限公司 本集團未經審核之業績 中國醫療網絡有限公司(「本公司」)之董事會(分別為「董事」及「董事會」)謹此宣 佈,本公司及其附屬公司(「本集團」)截至二零二零年六月三十日止六個月之未經審 核綜合業績連同截至二零一九年度同期之比較數字如下:- 簡明綜合損益表 截至二零二零年六月三十日止六個月 | --- | --- | --- | --- | |--------------------------------|-------|------------------------------------|---------------------------------------------------------| ...
中国医疗网络(00383) - 2019 - 年度财报
2020-04-28 11:28
Financial Performance - For the eighteen months ending December 31, 2019, the group recorded a revenue decline of HKD 2,042,090,000, compared to HKD 2,318,159,000 in 2018, with a profit attributable to shareholders of HKD 2,176,000, recovering from a loss of HKD 137,110,000 in the previous fiscal year[8]. - The healthcare segment generated revenue of HKD 1,622,141,000, up from HKD 964,563,000 in 2018, with a profit of HKD 35,733,000 compared to HKD 5,226,000 in 2018[14]. - EBITDA for the healthcare segment was HKD 239,760,000, an increase from HKD 130,387,000 in 2018[14]. - The company did not recommend a final dividend for the eighteen months ending December 31, 2019, consistent with no dividend in 2018[10]. - The revenue from the elderly care business reached HKD 150,272,000, an increase from HKD 100,753,000 in the previous year, with a reduced loss of HKD 44,322,000 compared to HKD 58,154,000[19]. - The property development segment recorded a revenue decrease of HKD 7,326,000, with a loss of HKD 5,031,000 compared to a profit of HKD 917,000 in the previous year[23]. - Rental income from investment properties was HKD 9,266,000, an increase from HKD 7,358,000, while profit decreased to HKD 15,434,000 from HKD 23,621,000[24]. - The securities trading and investment segment saw a revenue drop to HKD 202,119,000 from HKD 1,224,445,000, but profit increased to HKD 14,474,000 from a loss of HKD 24,366,000[25]. - The company implemented cost reduction and restructuring measures to improve financial performance starting from the second half of 2018[19]. - The group recorded interest income from lending activities of HKD 50,966,000 in 2019, significantly up from HKD 2,308,000 in 2018, with a profit of HKD 46,669,000 compared to HKD 2,247,000 in the previous year[31]. Healthcare Services - The Nanjing Hospital, the flagship facility, currently operates 39 clinical departments and plans to increase its bed capacity to 1,200 following renovations[15]. - The Nanjing Hospital has established a stroke center and has been included in the second batch of municipal chest pain and trauma centers to enhance emergency services[15]. - Kunming Hospital currently operates 30 clinical medical technology departments and has recruited renowned experts from other top-tier hospitals[16]. - Nanjing Hospital recorded 1,236,573 outpatient visits, 43,384 inpatient admissions, and 75,869 health check-ups, while Kunming Hospital had 334,678 outpatient visits, 20,634 inpatient admissions, and 113,008 health check-ups[16]. - The group is focused on expanding its healthcare services and enhancing its operational efficiency through strategic investments and management improvements[12]. - Nanjing Hospital plans to enhance talent development and improve medical technology and service innovation capabilities in 2020[49]. - Kunming Hospital aims to maintain stable business growth and improve overall medical quality while developing a modern nuclear medicine center[51]. Financial Position and Assets - As of December 31, 2019, the group's total borrowings reached HKD 793,363,000, a decrease from HKD 825,503,000 in 2018[33]. - The group's non-current assets amounted to HKD 2,222,623,000 as of December 31, 2019, slightly down from HKD 2,285,771,000 in 2018[32]. - The debt ratio calculated based on net borrowings to total equity was 7.5% as of December 31, 2019, down from 13.8% in 2018[35]. - The group's investment portfolio performance is generally influenced by global and regional economic, political, and financial market conditions[30]. - The group's total assets included investment properties valued at HKD 772,520,000 as of December 31, 2019[32]. - The investment property portfolio's total book value was HKD 512,000,000, down from HKD 524,376,000 in the previous year[21]. Corporate Governance - The company has a strong board with members holding significant experience in finance and management across various sectors, enhancing its strategic decision-making capabilities[65][66]. - The board includes independent directors with extensive backgrounds in finance and engineering, ensuring diverse perspectives in governance[70][71]. - The company has implemented measures to maintain high standards of corporate governance, which is considered crucial for enhancing shareholder value[111]. - The board consists of 11 members, including 4 executive directors, 3 non-executive directors, and 4 independent non-executive directors[112]. - The company has established governance functions to assist the board in monitoring management's business activities[146]. - The company has adopted a board diversity policy to enhance sustainable and balanced development, considering factors such as gender, age, and professional experience[145]. - The company has arranged training for new directors to ensure they understand their roles and responsibilities under regulatory requirements[119]. - The company has established a comprehensive internal control system with a clear organizational structure and defined responsibilities to ensure effective checks and balances[172]. Environmental Management - The company is committed to reducing the adverse impact of its operations on the natural environment and adheres to relevant environmental laws and regulations[198]. - The company has not reported any serious violations of environmental laws and regulations during the reporting period[198]. - The medical wastewater generated by the group’s hospitals during the period was 339,470 cubic meters, an increase from 237,047 cubic meters in 2018[199]. - The group has implemented three key principles for wastewater treatment: on-site treatment, integrated compliance and risk management, and ecological safety[200]. - The hospitals are equipped with efficient wastewater treatment systems that comply with the national wastewater discharge standards (GB8978-1996) at the tertiary level[200]. - Additional biochemical treatment processes have been added to upgrade the system and enhance environmental standards for wastewater discharge[200]. - Real-time monitoring equipment has been installed in the wastewater treatment system to ensure operational effectiveness and compliance with regulatory requirements[200]. Future Outlook - The group anticipates a challenging operating environment due to the impact of COVID-19 but remains optimistic about the long-term prospects of the private healthcare and elderly care sectors in China[48]. - The company is in discussions with the borrower regarding the total debt repayment and is monitoring the repayment progress closely[56]. - The company will maintain a prudent approach in light of global economic uncertainties, including the impact of COVID-19 and geopolitical tensions, while seeking investment opportunities in China, Hong Kong, and the Asia-Pacific region[57]. - Future outlook includes a focus on sustainable growth and innovation to meet evolving market demands[69].
中国医疗网络(00383) - 2019 - 中期财报
2019-09-29 22:22
China Medical & HealthCare Group Limited 中 國 醫 療 網 絡 有 限 公 司 ˚ (於百ङ建註冊成立之有限公司) (股份代號: 383) 二零一九年 第二份中期報告 中文名詞庫的藏宗 中國醫療網絡有限公司 本集團未經審核之業績 中國醫療網絡有限公司(「本公司」)之董事會(分別為「董事」及「董事會」)謹此宣 佈,本公司及其附屬公司(「本集團」)截至二零一九年六月三十日止十二個月之未經 審核綜合業績連同截至二零一八年度同期之比較數字如下:- 簡明綜合損益表 截至二零一九年六月三十日止十二個月 | --- | --- | --- | --- | |--------------------------------|-------|-----------------------------------------------------------------|--------------------------------| | | 附註 | 截至六月三十日止十二個月 \n二零一九年 千港元 \n(未經審核) | 二零一八年 千港元 \n(經審核) | | 收入 | 3 | ...